Zavante Overview

  • Founded
  • 2014
  • Status
  • Acquired/​Merged
  • Employees
  • 8
  • Latest Deal Type
  • M&A
  • Latest Deal Amount
  • $97.5M
Latest Deal Amount

Zavante General Information


Developer of novel medicines for the treatment of diseases that affect patients in the hospital setting. The company's lead product candidate is an investigational, first-in-class injectable antibiotic under development to combat serious, life-threatening infections, including those due to multi-drug resistant (MDR) Gram-negative and Gram-positive bacteria.

Contact Information

Ownership Status
Financing Status
Formerly VC-backed
Primary Industry
Other Industries
Drug Discovery
Primary Office
  • 11750 Sorrento Valley Road
  • Suite 250
  • San Diego, CA 92121
  • United States
+1 (858) 000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Zavante Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Merger/Acquisition 24-Jul-2018 $97.5M 000.00 000.00 Completed Generating Revenue
2. Debt - General 01-Sep-2016 0000 000.00 Completed Generating Revenue
1. Early Stage VC (Series A) 04-Apr-2016 $45.7M $45.7M 000.00 Completed Generating Revenue
To view Zavante’s complete valuation and funding history, request access »

Zavante Cap Table

Stock # of Shares
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A 00,000,000 00.000000 00.00 00.00 00.00 00 00.00 00.000
To view Zavante’s complete cap table history, request access »

Zavante Executive Team (13)

Name Title Board Seat Contact Info
Kevin Finney Chief Operating Officer
Evelyn Ellis-Grosse Ph.D Co-Founder & Chief Scientific Officer
Robert DiVasto Senior Vice President, Manufacturing & Supply
David Skarinsky Vice President, Clinical Operations
Kristina Haeckl Vice President of Regulatory Affairs & Quality Systems
You’re viewing 5 of 13 executive team members. Get the full list »

Zavante Board Members (7)

Name Representing Role Since
Cam Garner Self Co-Founder & Chairman 000 0000
Theodore Schroeder Self Co-Founder, Chief Executive Officer, President & Board Member 000 0000
You’re viewing 2 of 7 board members. Get the full list »

Zavante Signals

Growth Rate

0.80% Weekly
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers


Similarweb Unique Visitors


Majestic Referring Domains


PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Zavante Former Investors (5)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Aisling Capital Venture Capital Minority 000 0000 000000 0
Frazier Healthcare Partners PE/Buyout Minority 000 0000 000000 0
Global Source Ventures Venture Capital Minority 000 0000 000000 0
Longitude Capital Venture Capital Minority 000 0000 000000 0
Mesa Verde Venture Partners Venture Capital Minority 000 0000 000000 0
To view Zavante’s complete investors history, request access »